



# Participate in a clinical trial for adults with recurrent glioblastoma

## What is this study about?

ReSPECT-GBM is an FDA-approved Phase 2 clinical trial sponsored by Plus Therapeutics, Inc. and is supported by the U.S. National Institutes of Health. The objective is to determine dose, safety, and efficacy of a single administration of a new targeted radiation therapy, REYOBIQ™ (rhenium re186 obisbameda), in adult patients diagnosed with recurrent glioblastoma.

## Patient Reimbursement

\$599 compensation for time and travel is available.

## Are you eligible?

This trial is for adult patients that have a recurrent glioblastoma despite conventional treatment.

## Interested in Learning More?

If you are interested in learning more about the ReSPECT-GBM clinical trial, please visit our website at <https://ReSPECT-Trials.com/GBM>, provide your doctor with ClinicalTrials.gov identifier NCT01906385, or contact a trial coordinator.

## Clinical Trial Sites and Principal Investigators

- > UT Health San Antonio (Texas) - Andrew Brenner, M.D., Ph.D.
- > UT Southwestern Medical Center (Texas) - Toral Patel, M.D.
- > Northshore University Hospital (New York) - Michael Schulder, M.D.
- > Ohio State University Cancer Center - Pierre Giglio, M.D.

## To Qualify

To qualify for this trial, the patient must:

- Be age 18 or older
- Have a recurrent malignant glioma
- Be able to undergo an MRI scan
- Have not taken Avastin medication in the past

## Contact

- For questions, Please Email:  
**ReSPECT@PlusTherapeutics.com**



NATIONAL TRIAL REFERENCE NUMBER: NCT01906385

When speaking with your doctor, please have the national trial reference number available.

Scan QR code with your phone to learn more